0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Adrenoleukodystrophy Treatment Market Research Report 2023
Published Date: March 2023
|
Report Code: QYRE-Auto-14J10425
Home | Market Reports | Health| Health Conditions| Genetic Disorders
Global Adrenoleukodystrophy Treatment Market Research Report 2022
BUY CHAPTERS

Global Adrenoleukodystrophy Treatment Market Research Report 2023

Code: QYRE-Auto-14J10425
Report
March 2023
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Adrenoleukodystrophy Treatment Market

Adrenoleukodystrophy refers to a rare genetic condition that causes the buildup of long chain fatty acids (VLCFAs) in the brain. ALD is led by a mutation in the ABCD1 gene on the X chromosome. The three types of adrenoleukodystrophy including Adrenomyelopathy, Childhood cerebral ALD and Addison’s disease. Childhood cerebral ALD is known to progress rapidly in children between the ages of 3 and 10.
The global Adrenoleukodystrophy Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Adrenoleukodystrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Adrenoleukodystrophy Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Adrenoleukodystrophy Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Adrenoleukodystrophy Treatment include bluebird bio, Orpheris, MedDay Pharmaceuticals, MINORYX THERAPEUTICS SL, Pfizer, Amgen, AstraZeneca, Abbott and agtc, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Adrenoleukodystrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenoleukodystrophy Treatment.
The Adrenoleukodystrophy Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Adrenoleukodystrophy Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adrenoleukodystrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Key Segmentations

By Company

  • bluebird bio
  • Orpheris
  • MedDay Pharmaceuticals
  • MINORYX THERAPEUTICS SL
  • Pfizer
  • Amgen
  • AstraZeneca
  • Abbott
  • agtc
  • ReceptoPharm
  • The Myelin Project
  • SOM Biotech
  • Viking Therapeutics
  • Nutra Pharma Corporation
  • Genetix Biotech
  • Magenta Therapeutics
  • NeuroVia
  • Novartis
  • CELGENE CORPORATION
  • Jazz Pharmaceuticals
  • Sanofi

Segment by Type

  • Oral Drugs
  • Parenteral Drugs

Segment by Application

  • Hospital
  • Clinic
  • Home Care

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Adrenoleukodystrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

Scope of Global Adrenoleukodystrophy Treatment Market Report

Report MetricDetails
Report NameGlobal Adrenoleukodystrophy Treatment Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral Drugs
1.2.3 Parenteral Drugs
1.3 Market by Application
1.3.1 Global Adrenoleukodystrophy Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adrenoleukodystrophy Treatment Market Perspective (2018-2029)
2.2 Adrenoleukodystrophy Treatment Growth Trends by Region
2.2.1 Global Adrenoleukodystrophy Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Adrenoleukodystrophy Treatment Historic Market Size by Region (2018-2023)
2.2.3 Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2024-2029)
2.3 Adrenoleukodystrophy Treatment Market Dynamics
2.3.1 Adrenoleukodystrophy Treatment Industry Trends
2.3.2 Adrenoleukodystrophy Treatment Market Drivers
2.3.3 Adrenoleukodystrophy Treatment Market Challenges
2.3.4 Adrenoleukodystrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue
3.1.1 Global Top Adrenoleukodystrophy Treatment Players by Revenue (2018-2023)
3.1.2 Global Adrenoleukodystrophy Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Adrenoleukodystrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adrenoleukodystrophy Treatment Revenue
3.4 Global Adrenoleukodystrophy Treatment Market Concentration Ratio
3.4.1 Global Adrenoleukodystrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adrenoleukodystrophy Treatment Revenue in 2022
3.5 Adrenoleukodystrophy Treatment Key Players Head office and Area Served
3.6 Key Players Adrenoleukodystrophy Treatment Product Solution and Service
3.7 Date of Enter into Adrenoleukodystrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adrenoleukodystrophy Treatment Breakdown Data by Type
4.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Type (2018-2023)
4.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2024-2029)
5 Adrenoleukodystrophy Treatment Breakdown Data by Application
5.1 Global Adrenoleukodystrophy Treatment Historic Market Size by Application (2018-2023)
5.2 Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Adrenoleukodystrophy Treatment Market Size (2018-2029)
6.2 North America Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
6.4 North America Adrenoleukodystrophy Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adrenoleukodystrophy Treatment Market Size (2018-2029)
7.2 Europe Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
7.4 Europe Adrenoleukodystrophy Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adrenoleukodystrophy Treatment Market Size (2018-2029)
8.2 Asia-Pacific Adrenoleukodystrophy Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adrenoleukodystrophy Treatment Market Size (2018-2029)
9.2 Latin America Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
9.4 Latin America Adrenoleukodystrophy Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adrenoleukodystrophy Treatment Market Size (2018-2029)
10.2 Middle East & Africa Adrenoleukodystrophy Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 bluebird bio
11.1.1 bluebird bio Company Detail
11.1.2 bluebird bio Business Overview
11.1.3 bluebird bio Adrenoleukodystrophy Treatment Introduction
11.1.4 bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.1.5 bluebird bio Recent Development
11.2 Orpheris
11.2.1 Orpheris Company Detail
11.2.2 Orpheris Business Overview
11.2.3 Orpheris Adrenoleukodystrophy Treatment Introduction
11.2.4 Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.2.5 Orpheris Recent Development
11.3 MedDay Pharmaceuticals
11.3.1 MedDay Pharmaceuticals Company Detail
11.3.2 MedDay Pharmaceuticals Business Overview
11.3.3 MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.3.4 MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.3.5 MedDay Pharmaceuticals Recent Development
11.4 MINORYX THERAPEUTICS SL
11.4.1 MINORYX THERAPEUTICS SL Company Detail
11.4.2 MINORYX THERAPEUTICS SL Business Overview
11.4.3 MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Introduction
11.4.4 MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.4.5 MINORYX THERAPEUTICS SL Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Adrenoleukodystrophy Treatment Introduction
11.5.4 Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Adrenoleukodystrophy Treatment Introduction
11.6.4 Amgen Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Adrenoleukodystrophy Treatment Introduction
11.7.4 AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.7.5 AstraZeneca Recent Development
11.8 Abbott
11.8.1 Abbott Company Detail
11.8.2 Abbott Business Overview
11.8.3 Abbott Adrenoleukodystrophy Treatment Introduction
11.8.4 Abbott Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.8.5 Abbott Recent Development
11.9 agtc
11.9.1 agtc Company Detail
11.9.2 agtc Business Overview
11.9.3 agtc Adrenoleukodystrophy Treatment Introduction
11.9.4 agtc Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.9.5 agtc Recent Development
11.10 ReceptoPharm
11.10.1 ReceptoPharm Company Detail
11.10.2 ReceptoPharm Business Overview
11.10.3 ReceptoPharm Adrenoleukodystrophy Treatment Introduction
11.10.4 ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.10.5 ReceptoPharm Recent Development
11.11 The Myelin Project
11.11.1 The Myelin Project Company Detail
11.11.2 The Myelin Project Business Overview
11.11.3 The Myelin Project Adrenoleukodystrophy Treatment Introduction
11.11.4 The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.11.5 The Myelin Project Recent Development
11.12 SOM Biotech
11.12.1 SOM Biotech Company Detail
11.12.2 SOM Biotech Business Overview
11.12.3 SOM Biotech Adrenoleukodystrophy Treatment Introduction
11.12.4 SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.12.5 SOM Biotech Recent Development
11.13 Viking Therapeutics
11.13.1 Viking Therapeutics Company Detail
11.13.2 Viking Therapeutics Business Overview
11.13.3 Viking Therapeutics Adrenoleukodystrophy Treatment Introduction
11.13.4 Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.13.5 Viking Therapeutics Recent Development
11.14 Nutra Pharma Corporation
11.14.1 Nutra Pharma Corporation Company Detail
11.14.2 Nutra Pharma Corporation Business Overview
11.14.3 Nutra Pharma Corporation Adrenoleukodystrophy Treatment Introduction
11.14.4 Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.14.5 Nutra Pharma Corporation Recent Development
11.15 Genetix Biotech
11.15.1 Genetix Biotech Company Detail
11.15.2 Genetix Biotech Business Overview
11.15.3 Genetix Biotech Adrenoleukodystrophy Treatment Introduction
11.15.4 Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.15.5 Genetix Biotech Recent Development
11.16 Magenta Therapeutics
11.16.1 Magenta Therapeutics Company Detail
11.16.2 Magenta Therapeutics Business Overview
11.16.3 Magenta Therapeutics Adrenoleukodystrophy Treatment Introduction
11.16.4 Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.16.5 Magenta Therapeutics Recent Development
11.17 NeuroVia
11.17.1 NeuroVia Company Detail
11.17.2 NeuroVia Business Overview
11.17.3 NeuroVia Adrenoleukodystrophy Treatment Introduction
11.17.4 NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.17.5 NeuroVia Recent Development
11.18 Novartis
11.18.1 Novartis Company Detail
11.18.2 Novartis Business Overview
11.18.3 Novartis Adrenoleukodystrophy Treatment Introduction
11.18.4 Novartis Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.18.5 Novartis Recent Development
11.19 CELGENE CORPORATION
11.19.1 CELGENE CORPORATION Company Detail
11.19.2 CELGENE CORPORATION Business Overview
11.19.3 CELGENE CORPORATION Adrenoleukodystrophy Treatment Introduction
11.19.4 CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.19.5 CELGENE CORPORATION Recent Development
11.20 Jazz Pharmaceuticals
11.20.1 Jazz Pharmaceuticals Company Detail
11.20.2 Jazz Pharmaceuticals Business Overview
11.20.3 Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Introduction
11.20.4 Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.20.5 Jazz Pharmaceuticals Recent Development
11.21 Sanofi
11.21.1 Sanofi Company Detail
11.21.2 Sanofi Business Overview
11.21.3 Sanofi Adrenoleukodystrophy Treatment Introduction
11.21.4 Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2018-2023)
11.21.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Adrenoleukodystrophy Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Oral Drugs
    Table 3. Key Players of Parenteral Drugs
    Table 4. Global Adrenoleukodystrophy Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 5. Global Adrenoleukodystrophy Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 7. Global Adrenoleukodystrophy Treatment Market Share by Region (2018-2023)
    Table 8. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 9. Global Adrenoleukodystrophy Treatment Market Share by Region (2024-2029)
    Table 10. Adrenoleukodystrophy Treatment Market Trends
    Table 11. Adrenoleukodystrophy Treatment Market Drivers
    Table 12. Adrenoleukodystrophy Treatment Market Challenges
    Table 13. Adrenoleukodystrophy Treatment Market Restraints
    Table 14. Global Adrenoleukodystrophy Treatment Revenue by Players (2018-2023) & (US$ Million)
    Table 15. Global Adrenoleukodystrophy Treatment Market Share by Players (2018-2023)
    Table 16. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2022)
    Table 17. Ranking of Global Top Adrenoleukodystrophy Treatment Companies by Revenue (US$ Million) in 2022
    Table 18. Global 5 Largest Players Market Share by Adrenoleukodystrophy Treatment Revenue (CR5 and HHI) & (2018-2023)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Adrenoleukodystrophy Treatment Product Solution and Service
    Table 21. Date of Enter into Adrenoleukodystrophy Treatment Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Adrenoleukodystrophy Treatment Market Size by Type (2018-2023) & (US$ Million)
    Table 24. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2018-2023)
    Table 25. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 26. Global Adrenoleukodystrophy Treatment Revenue Market Share by Type (2024-2029)
    Table 27. Global Adrenoleukodystrophy Treatment Market Size by Application (2018-2023) & (US$ Million)
    Table 28. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2018-2023)
    Table 29. Global Adrenoleukodystrophy Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 30. Global Adrenoleukodystrophy Treatment Revenue Market Share by Application (2024-2029)
    Table 31. North America Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 32. North America Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 33. North America Adrenoleukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 34. Europe Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 35. Europe Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 36. Europe Adrenoleukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 37. Asia-Pacific Adrenoleukodystrophy Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 38. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 39. Asia-Pacific Adrenoleukodystrophy Treatment Market Size by Region (2024-2029) & (US$ Million)
    Table 40. Latin America Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 41. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 42. Latin America Adrenoleukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 43. Middle East & Africa Adrenoleukodystrophy Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 44. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 45. Middle East & Africa Adrenoleukodystrophy Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 46. bluebird bio Company Detail
    Table 47. bluebird bio Business Overview
    Table 48. bluebird bio Adrenoleukodystrophy Treatment Product
    Table 49. bluebird bio Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 50. bluebird bio Recent Development
    Table 51. Orpheris Company Detail
    Table 52. Orpheris Business Overview
    Table 53. Orpheris Adrenoleukodystrophy Treatment Product
    Table 54. Orpheris Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 55. Orpheris Recent Development
    Table 56. MedDay Pharmaceuticals Company Detail
    Table 57. MedDay Pharmaceuticals Business Overview
    Table 58. MedDay Pharmaceuticals Adrenoleukodystrophy Treatment Product
    Table 59. MedDay Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 60. MedDay Pharmaceuticals Recent Development
    Table 61. MINORYX THERAPEUTICS SL Company Detail
    Table 62. MINORYX THERAPEUTICS SL Business Overview
    Table 63. MINORYX THERAPEUTICS SL Adrenoleukodystrophy Treatment Product
    Table 64. MINORYX THERAPEUTICS SL Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 65. MINORYX THERAPEUTICS SL Recent Development
    Table 66. Pfizer Company Detail
    Table 67. Pfizer Business Overview
    Table 68. Pfizer Adrenoleukodystrophy Treatment Product
    Table 69. Pfizer Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 70. Pfizer Recent Development
    Table 71. Amgen Company Detail
    Table 72. Amgen Business Overview
    Table 73. Amgen Adrenoleukodystrophy Treatment Product
    Table 74. Amgen Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 75. Amgen Recent Development
    Table 76. AstraZeneca Company Detail
    Table 77. AstraZeneca Business Overview
    Table 78. AstraZeneca Adrenoleukodystrophy Treatment Product
    Table 79. AstraZeneca Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 80. AstraZeneca Recent Development
    Table 81. Abbott Company Detail
    Table 82. Abbott Business Overview
    Table 83. Abbott Adrenoleukodystrophy Treatment Product
    Table 84. Abbott Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 85. Abbott Recent Development
    Table 86. agtc Company Detail
    Table 87. agtc Business Overview
    Table 88. agtc Adrenoleukodystrophy Treatment Product
    Table 89. agtc Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 90. agtc Recent Development
    Table 91. ReceptoPharm Company Detail
    Table 92. ReceptoPharm Business Overview
    Table 93. ReceptoPharm Adrenoleukodystrophy Treatment Product
    Table 94. ReceptoPharm Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 95. ReceptoPharm Recent Development
    Table 96. The Myelin Project Company Detail
    Table 97. The Myelin Project Business Overview
    Table 98. The Myelin Project Adrenoleukodystrophy Treatment Product
    Table 99. The Myelin Project Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 100. The Myelin Project Recent Development
    Table 101. SOM Biotech Company Detail
    Table 102. SOM Biotech Business Overview
    Table 103. SOM Biotech Adrenoleukodystrophy Treatment Product
    Table 104. SOM Biotech Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 105. SOM Biotech Recent Development
    Table 106. Viking Therapeutics Company Detail
    Table 107. Viking Therapeutics Business Overview
    Table 108. Viking Therapeutics Adrenoleukodystrophy Treatment Product
    Table 109. Viking Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 110. Viking Therapeutics Recent Development
    Table 111. Nutra Pharma Corporation Company Detail
    Table 112. Nutra Pharma Corporation Business Overview
    Table 113. Nutra Pharma Corporation Adrenoleukodystrophy Treatment Product
    Table 114. Nutra Pharma Corporation Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 115. Nutra Pharma Corporation Recent Development
    Table 116. Genetix Biotech Company Detail
    Table 117. Genetix Biotech Business Overview
    Table 118. Genetix Biotech Adrenoleukodystrophy Treatment Product
    Table 119. Genetix Biotech Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 120. Genetix Biotech Recent Development
    Table 121. Magenta Therapeutics Company Detail
    Table 122. Magenta Therapeutics Business Overview
    Table 123. Magenta Therapeutics Adrenoleukodystrophy Treatment Product
    Table 124. Magenta Therapeutics Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 125. Magenta Therapeutics Recent Development
    Table 126. NeuroVia Company Detail
    Table 127. NeuroVia Business Overview
    Table 128. NeuroVia Adrenoleukodystrophy Treatment Product
    Table 129. NeuroVia Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 130. NeuroVia Recent Development
    Table 131. Novartis Company Detail
    Table 132. Novartis Business Overview
    Table 133. Novartis Adrenoleukodystrophy Treatment Product
    Table 134. Novartis Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 135. Novartis Recent Development
    Table 136. CELGENE CORPORATION Company Detail
    Table 137. CELGENE CORPORATION Business Overview
    Table 138. CELGENE CORPORATION Adrenoleukodystrophy Treatment Product
    Table 139. CELGENE CORPORATION Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 140. CELGENE CORPORATION Recent Development
    Table 141. Jazz Pharmaceuticals Company Detail
    Table 142. Jazz Pharmaceuticals Business Overview
    Table 143. Jazz Pharmaceuticals Adrenoleukodystrophy Treatment Product
    Table 144. Jazz Pharmaceuticals Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 145. Jazz Pharmaceuticals Recent Development
    Table 146. Sanofi Company Detail
    Table 147. Sanofi Business Overview
    Table 148. Sanofi Adrenoleukodystrophy Treatment Product
    Table 149. Sanofi Revenue in Adrenoleukodystrophy Treatment Business (2018-2023) & (US$ Million)
    Table 150. Sanofi Recent Development
    Table 151. Research Programs/Design for This Report
    Table 152. Key Data Information from Secondary Sources
    Table 153. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Adrenoleukodystrophy Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Adrenoleukodystrophy Treatment Market Share by Type: 2022 VS 2029
    Figure 3. Oral Drugs Features
    Figure 4. Parenteral Drugs Features
    Figure 5. Global Adrenoleukodystrophy Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 6. Global Adrenoleukodystrophy Treatment Market Share by Application: 2022 VS 2029
    Figure 7. Hospital Case Studies
    Figure 8. Clinic Case Studies
    Figure 9. Home Care Case Studies
    Figure 10. Adrenoleukodystrophy Treatment Report Years Considered
    Figure 11. Global Adrenoleukodystrophy Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 12. Global Adrenoleukodystrophy Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 13. Global Adrenoleukodystrophy Treatment Market Share by Region: 2022 VS 2029
    Figure 14. Global Adrenoleukodystrophy Treatment Market Share by Players in 2022
    Figure 15. Global Top Adrenoleukodystrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adrenoleukodystrophy Treatment as of 2022)
    Figure 16. The Top 10 and 5 Players Market Share by Adrenoleukodystrophy Treatment Revenue in 2022
    Figure 17. North America Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 18. North America Adrenoleukodystrophy Treatment Market Share by Country (2018-2029)
    Figure 19. United States Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 20. Canada Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. Europe Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Europe Adrenoleukodystrophy Treatment Market Share by Country (2018-2029)
    Figure 23. Germany Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 24. France Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. U.K. Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. Italy Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Russia Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Nordic Countries Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Asia-Pacific Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Asia-Pacific Adrenoleukodystrophy Treatment Market Share by Region (2018-2029)
    Figure 31. China Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 32. Japan Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. South Korea Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. Southeast Asia Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. India Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. Australia Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Latin America Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Latin America Adrenoleukodystrophy Treatment Market Share by Country (2018-2029)
    Figure 39. Mexico Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 40. Brazil Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Middle East & Africa Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Middle East & Africa Adrenoleukodystrophy Treatment Market Share by Country (2018-2029)
    Figure 43. Turkey Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 44. Saudi Arabia Adrenoleukodystrophy Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. bluebird bio Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 46. Orpheris Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 47. MedDay Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 48. MINORYX THERAPEUTICS SL Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 49. Pfizer Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 50. Amgen Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 51. AstraZeneca Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 52. Abbott Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 53. agtc Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 54. ReceptoPharm Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 55. The Myelin Project Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 56. SOM Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 57. Viking Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 58. Nutra Pharma Corporation Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 59. Genetix Biotech Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 60. Magenta Therapeutics Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 61. NeuroVia Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 62. Novartis Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 63. CELGENE CORPORATION Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 64. Jazz Pharmaceuticals Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 65. Sanofi Revenue Growth Rate in Adrenoleukodystrophy Treatment Business (2018-2023)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Patau Syndrome Genetic Testing Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-36X5739
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Edwards Syndrome Genetic Testing Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-29E5753
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Thalassemia Gene Detection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-25M5726
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Phenylketonuria Treatment Product Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-34D5897
Mon Feb 19 00:00:00 UTC 2024

Add to Cart